SubHero Banner
Text

Pepaxto® (melphalan flufenamide) – Safety update

July 28, 2021 - The FDA alerted patients and health care professionals that a clinical trial (OCEAN, Study OP-103) evaluating Pepaxto (melphalan flufenamide) with dexamethasone to treat patients with multiple myeloma showed an increased risk of death.

Download PDF